How India Exports Everolimus to the World

In the United States, everolimus is marketed under the brand name Afinitor, with initial FDA approval granted to Novartis Pharmaceuticals Corporation on March 30, 2009, for the treatment of advanced renal cell carcinoma. Subsequent approvals expanded its indications to include progressive neuroendocrine tumors of pancreatic origin (May 5, 2011) and progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin (February 26, 2016).

The FDA has approved generic versions of Afinitor; however, the availability of these generics in the market can be influenced by existing patents or exclusivity rights. As of March 2026, there are no active FDA import alerts specifically targeting everolimus, indicating compliance with U.S. regulatory standards.

The substantial export volume of everolimus from India to the U.S., accounting for 50.5% of total exports, underscores the importance of Indian manufacturers in the U.S. pharmaceutical supply chain. The presence of 87 active Indian exporters reflects a competitive landscape, necessitating strict adherence to FDA regulations to maintain market access.

In the European Union, everolimus is authorized under the brand name Afinitor, with the European Medicines Agency (EMA) granting marketing authorization on August 3, 2009, for the treatment of advanced renal cell carcinoma. The authorization has since been extended to include other indications, such as certain types of breast cancer and neuroendocrine tumors. (ema.europa.eu)

The United Kingdom, following its departure from the EU, continues to recognize EMA approvals through the Medicines and Healthcare products Regulatory Agency (MHRA). Manufacturers exporting everolimus to these markets must comply with EU Good Manufacturing Practice (GMP) standards, ensuring product quality and safety.

Everolimus is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its significance in treating priority health conditions. (who.int) Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for manufacturers to ensure global acceptance and quality assurance of everolimus products.

In India, everolimus is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for everolimus, allowing market-driven pricing. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

The primary patents for everolimus have expired, leading to increased generic competition. This has resulted in a more competitive market landscape, with multiple manufacturers producing and exporting the drug. The presence of 87 active Indian exporters reflects this competitive environment, emphasizing the need for stringent quality control and regulatory compliance to maintain market share.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines updated the Model List to its 24th edition, reaffirming the inclusion of everolimus for specific indications. (who.int)

In September 2025, the WHO launched a digital version of its Model List of Essential Medicines, enhancing accessibility and facilitating the integration of essential medicines like everolimus into national healthcare systems. (who.int)

These developments underscore the global recognition of everolimus's therapeutic value and the ongoing efforts to ensure its availability and proper use in healthcare systems worldwide.

India's pharmaceutical industry, including the production of Everolimus, heavily relies on Key Starting Materials (KSMs) sourced from China. Approximately 70–80% of global KSM supply is controlled by China, making it a dominant player in this sector. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact Indian API manufacturing. For instance, in 2025, environmental regulations led to the shutdown of numerous Chinese factories, causing a surge in KSM prices and subsequent challenges for Indian pharmaceutical companies.

The Indian government has initiated measures like the Production Linked Incentive (PLI) scheme to bolster domestic production of APIs and KSMs, aiming to reduce reliance on imports. However, as of November 2024, while two greenfield plants were inaugurated under this scheme to manufacture critical molecules, the overall impact on reducing import dependence remains to be fully realized.

Our proprietary trade data indicates a high supplier concentration in Everolimus exports from India, with the top five exporters accounting for 95.9% of the market. Notably, NATCO PHARMA LIMITED alone holds a 52.8% share. Such concentration heightens the risk of supply disruptions, as any operational or regulatory issues affecting these key players could significantly impact global supply chains.

The PLI scheme aims to diversify and strengthen the supplier base by incentivizing new entrants into the API manufacturing sector. However, the effectiveness of this initiative in mitigating single-source risks is contingent upon its successful implementation and the establishment of a robust domestic manufacturing ecosystem.

Recent geopolitical tensions have further exacerbated supply chain vulnerabilities. The 2026 Strait of Hormuz crisis, which began in March 2026, led to significant disruptions in global shipping routes, affecting the transportation of pharmaceuticals and other critical goods. This crisis resulted in a sharp decline in maritime transit, with tanker traffic dropping by approximately 70% and over 150 ships anchoring outside the strait to avoid risks.

Additionally, the ongoing Iran war has severely disrupted global supply chains, primarily by halting oil tanker movement through the critical Strait of Hormuz. This choke point is essential for global commerce, affecting not only oil supply but also the distribution of pharmaceuticals from India.

• Diversify API and KSM Sourcing: Encourage the development of alternative sources for APIs and KSMs, both domestically and from other countries, to reduce dependency on a single nation.

• Strengthen Domestic Manufacturing: Accelerate the implementation of the PLI scheme and similar initiatives to bolster domestic production capabilities for critical pharmaceutical components.

• Enhance Supply Chain Transparency: Implement robust tracking and monitoring systems to identify potential disruptions early and develop contingency plans accordingly.

• Invest in Infrastructure: Develop resilient logistics and transportation networks to mitigate the impact of geopolitical disruptions on supply chains.

• Foster International Collaboration: Engage in strategic partnerships and agreements with other nations to ensure a stable and diversified supply of pharmaceutical ingredients.

RISK_LEVEL: HIGH